Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247 | Executive Vice President | November 11, 2021 | November 15, 2021 |
| Telesis Bio Inc.TBIO · Entity 15606 | Director | July 06, 2023 | May 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date November 11, 2021 · Filed November 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 4,593.3476 |
Ending reported balance
After 2021-11-12 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2021-11-11 · Exercise / conversion · Acquired 613 · Balance 5,206.3476 Row 2 · 2021-11-11 · Exercise / conversion · Acquired 500 · Balance 5,706.3476 Row 3 · 2021-11-11 · Exercise / conversion · Acquired 433 · Balance 6,139.3476 Row 4 · 2021-11-11 · Sale · Disposed 433 · Balance 5,706.3476 Row 5 · 2021-11-11 · Sale · Disposed 613 · Balance 5,093.3476 Row 6 · 2021-11-11 · Sale · Disposed 500 · Balance 4,593.3476 Row 7 · 2021-11-12 · Exercise / conversion · Acquired 600 · Balance 5,193.3476 Row 8 · 2021-11-12 · Exercise / conversion · Acquired 2,400 · Balance 7,593.3476 Row 9 · 2021-11-12 · Exercise / conversion · Acquired 1,800 · Balance 9,393.3476 Row 10 · 2021-11-12 · Sale · Disposed 4,800 · Balance 4,593.3476 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $524.30 · Expires 2030-09-02 | Direct | 1,300 |
Reported balance
After 2021-11-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-11 · Exercise / conversion · Disposed 433 · Balance 1,300 F2: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $333.34 · Expires 2029-09-03 | Direct | 1,671 |
Reported balance
After 2021-11-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-11-11 · Exercise / conversion · Disposed 1,113 · Balance 1,671 F3: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $326.15 · Expires 2028-09-04 | Direct | 1,200 |
Reported balance
After 2021-11-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-12 · Exercise / conversion · Disposed 1,800 · Balance 1,200 F4: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $215.98 · Expires 2027-09-05 | Direct | 600 |
Reported balance
After 2021-11-12 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-11-12 · Exercise / conversion · Disposed 2,400 · Balance 600 F5: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $159.32 · Expires 2026-09-07 | Direct | 0 |
Reported balance
After 2021-11-12 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-11-12 · Exercise / conversion · Disposed 600 · Balance 0 F6: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.00 to $750.61, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option, representing a right to purchase a total of 1,733 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted.
F3: The option, representing a right to purchase a total of 2,784 shares, became exercisable in five equal annual installments beginning on September 3, 2020, which was the first anniversary of the date on which the option was granted.
F4: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 4, 2019, which was the first anniversary of the date on which the option was granted.
F5: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.
F6: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.
Telesis Bio Inc.
Report date July 06, 2023 · Filed May 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,769 |
Ending reported balance
After 2024-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-06 · Grant · Acquired 46,752 · Balance 121,363 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. Row 2 · 2024-05-01 · Grant · Acquired 36,406 · Balance 157,769 F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,165 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2033-07-06 | Direct | 70,129 |
Reported balance
After 2023-07-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-06 · Grant · Acquired 70,129 · Balance 70,129 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2034-05-01 | Direct | 30,362 |
Reported balance
After 2024-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-01 · Grant · Acquired 30,362 · Balance 30,362 F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Issuer's 2021 Stock Incentive Plan (the "Plan")) through such date, 100% of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F2: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through each applicable date, 16,165 of the RSUs shall vest on January 1, 2025, and 20,241 of the RSUs shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
F3: Subject to the Reporting Person continuing as a Service Provider (as defined in the Plan) through such date, 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the date of grant or on the date of the annual meeting of the Issuer's stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 247 | $484.23 | $119,604.81 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,518.3476 Read SEC document |
| September 05, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,765.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · derivative · entry 7 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $484.23 | $100,719.84 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,165.3476 Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 17:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000029 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,373.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 17:00 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 556 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000022 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 Underlying: Bio-Rad A Common Stock · 556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 3, 2020. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 3, 2020. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 17:00 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 193 | $494.24 | $95,388.32 |
DisclosureSEC source: 0001315406-20-000022 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,773.3476 Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 17:00 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 556 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-20-000022 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,733 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001812865-20-000014 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires 2030-09-02 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 19:44 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 1,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000014 · edgar.xml · derivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733 Underlying: Bio-Rad A Common Stock · 1,733 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:05 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 522 | $330.00 | $172,260.00 |
DisclosureSEC source: 0001652252-19-000075 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410.3476 Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · derivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 238 | $326.42 | $77,687.96 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,932.3476 Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · derivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 139 | $322.93 | $44,887.27 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570.3476 Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000073 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · derivative · entry 7 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $335.59 | $69,802.72 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309.3476 Read SEC document |
| September 07, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 371 | $340.00 | $126,140.00 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,917.3476 Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · derivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $339.48 | $70,611.84 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,288.3476 Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 21:36 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000049 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,496.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 18:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000035 · edgar.xml · derivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. F5 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 4, 2019. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 18:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $335.20 | $69,721.60 |
DisclosureSEC source: 0001652252-19-000035 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896.3476 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 18:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000035 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,104.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 18:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,784 | $0.00 Strike: $333.34 | $0.00 |
DisclosureSEC source: 0001652252-19-000035 · edgar.xml · derivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,784 Underlying: Bio-Rad A Common Stock · 2,784 shares Expires 2029-09-03 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 18:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 2,784 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-19-000035 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,784 Underlying: Bio-Rad A Common Stock · 2,784 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-18-000091 · edgar.xml · derivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in five equal annual installments beginning September 7, 2017 Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 1,200 | $255.00 | $306,000.00 |
DisclosureSEC source: 0001652252-18-000091 · edgar.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504.3476 Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,200 | $159.32 | $191,184.00 |
DisclosureSEC source: 0001652252-18-000091 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,704.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:07 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 1,176 | $254.00 | $298,704.00 |
DisclosureSEC source: 0001652252-18-000091 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504.3476 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:38 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000089 · edgar.xml · derivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:38 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000089 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:38 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 347 | $308.37 | $107,004.39 |
DisclosureSEC source: 0001652252-18-000089 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,680.3476 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:38 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000089 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,027.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:06 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000069 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:06 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 139 | $308.00 | $42,812.00 |
DisclosureSEC source: 0001652252-18-000069 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,027.3476 Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:06 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000069 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:46 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000056 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:46 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $313.74 | $65,257.92 |
DisclosureSEC source: 0001652252-18-000056 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766.3476 Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 18:46 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000056 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 18:41 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000035 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 5, 2018. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 18:41 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 208 | $315.50 | $65,624.00 |
DisclosureSEC source: 0001652252-18-000035 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374.3476 Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 18:41 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000035 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:25 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000019 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2028-09-04 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:25 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000019 · edgar.xml · derivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.